Download Solid Tumor

Solid
Tumor
Archer™ FusionPlex™ Solid Tumor Panel
Carcinoma Incidence and Mortality
The Archer FusionPlex Solid Tumor Panel is a targeted
sequencing assay that simultaneously detects and
identifies fusions and other mutations in over 50 genes
linked to carcinomas and other solid tumors.
Life-threatening carcinomas make up over 80% of all
cancers(1). In the United States, prostate cancer has the
highest incidence rate, followed closely by female breast
cancer, and lung cancer has by far the highest mortality rate.
The power of the FusionPlex Solid Tumor panel lies
in proprietary Anchored Multiplex PCR (AMP)™-based
enrichment. This chemistry enables detection of all
fusions associated with the genes in this panel in a single
sequencing assay, even without prior knowledge of fusion
partners or breakpoints.
Leading Cancer Rates by Site
(1)
Male and Female, United States
(per 100,000 persons)
150
100
50
0
50
Lung and Bronchus
Prostate
Female Breast
Non-Hodgkin Lymphoma
Colon and Rectum
Urinary Bladder
Incidence Rate
• Comprehensive – identify carcinoma-related
fusions in a single assay
• Detailed – characterize fusion partners at
single-nucleotide resolution
• Streamlined – reduce turn-around time and
eliminate reflex testing
• Flexible – works with all clinical sample types,
including FFPE; only 20ng RNA input required
For Research Use Only. Not for use in diagnostic procedures.
Learn more about the Solid Tumor Panel at
www.archerdx.com/solid-tumor
Mortality Rate
Assay Targets
The panel includes specific breakpoints of the following
genes.
AKT3
EWSR1
NOTCH1/2
RAF1
ALK
FGFR1/2/3
NRG1
RELA
ARHGAP26
FGR
NTRK1/2/3
RET
AXL
INSR
NUMBL
ROS1
BRAF
MAML2
NUTM1
RSPO2/3
BRD3/4
MAST1/2
PDGFRA/B
TERT
EGFR
MET
PIK3CA
TFE3
ERG
MSMB
PKN1
TFEB
ESR1
MUSK
PPARG
THADA
ETV1/4/5/6
MYB
PRKCA/B
TMPRSS2
(1) Visit archerdx.com/solid-tumor for references
Receptor-mediated growth,
proliferation and survival pathways
Gene targets in the FusionPlex Solid
Tumor Panel are shaded
Receptor tyrosine kinases
ALK
EGFR
FGR
MET
NTRK 1,2,3
PDGFRB
ROS1
NRG1
NRG1
Ca2+
AXL
FGFR 1,2,3
INSR
MuSK
PDGFRA
RET
Notch receptors
NOTCH1 NOTCH2
Wnt
Frizzled receptor
PDK2 PDK1
GRB2 SHC PLC
SOS
PIP2
Ca2+
AKT
p85
DAG
β-catenin
PI3KCA
PTEN
Apoptosis
RAS-activated kinases
BRAF RAF1
AKT3
PI3K
p110
RAS
PIP3
Protein kinase C (PKC)
PRKCA PRKCB
R-spondins
RSPO2 RSPO3
Notch ICD
•proliferation
•cell survivial
Protein
synthesis
Transcription factors/
RNA metabolism
MAP kinase cascade:
•cell proliferation
•survival
•differentation
BRD3
ESR1
MAML2
PPARG
TFEB
Assay targets for oncogenic fusion detection
include:
• Receptor tyrosine kinases and ligand
• MAP kinases
• Tumor suppressors
• Wnt signaling effectors
• Transcription factors
BRD4
ETV1,4,5,6
MYB
RELA
ERG
EWSR1
NUT
TFE3
c-MYC
PTEN
Visualize Fusion Detection with
Single Nucleotide Resolution
The FusionPlex Solid Tumor Panel in conjunction Archer
Analysis software is optimized to detect both known and
novel fusions.
Superior Performance
The FusionPlex Solid Tumor Panel demonstrates
superior on-target and uniformity metrics using
clinically relevant samples.
FGFR2-PCM1
fusion annotations
Read depth
FusionPlex Solid Tumor
performance metrics by input type
100
80
60
% on-target
40
% coverage
uniformity*
20
0
Individual
reads
Adrenal
gDNA
Lung RNA
Thyroid
RNA
Colon RNA
FFPE Lung
Tumor RNA
*coverage uniformity ≥ 0.2x of the median
Sequencing pileup of reads across FGFR2 exon 17
into the PCM1 gene, indicating an FGFR2-PCM1 fusion
archerdx.com
PN-MKT-0029 REV A